Who
Bahram Valamehr
President and CEO
Company insider
Files Form 4 as: President and CEO, Fate Therapeutics.
In numbers
- Trades disclosed
- 103
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $14.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Jan 2019
- Last trade
- 4 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 5 Aug 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K43,947 at $2.46 | filing |
| 4 Aug 2026filed 5 Aug 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K43,947 at $2.46 | filing |
| 20 May 2026filed 21 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $54K28,946 at $1.88 | filing |
| 20 May 2026filed 21 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $54K28,946 at $1.88 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —335,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,300,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,300,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —335,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,5575,190 at $1.07 | filing |
| 9 Jan 2026filed 12 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,5535,190 at $1.07 | filing |
| 4 Aug 2025filed 5 Aug 2025 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K14,466 at $1.06 | filing |
| 16 Jan 2025filed 16 Jan 2025 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,300,000 at $0.00 | filing |
| 10 Jan 2025filed 13 Jan 2025 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K8,705 at $1.54 | filing |
| 29 Jul 2024filed 31 Jul 2024 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 1 Feb 2024filed 2 Feb 2024 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 9 Jan 2024filed 10 Jan 2024 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $49K11,271 at $4.38 | filing |
| 6 Feb 2023filed 7 Feb 2023 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 12 Jan 2023filed 13 Jan 2023 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —423 at $0.00 | filing |
| 12 Jan 2023filed 13 Jan 2023 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $580423 at $1.37 | filing |
| 10 Jan 2023filed 11 Jan 2023 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $57K10,917 at $5.24 | filing |
News
Analyzing Fate Therapeutics (NASDAQ:FATE) & Applied Therapeutics (NASDAQ:APLT)FATE · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Bahram Valamehr; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.